echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Innovative drug HSK21542 injection, a wholly-owned subsidiary of Haisco obtains clinical approval

    Innovative drug HSK21542 injection, a wholly-owned subsidiary of Haisco obtains clinical approval

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 2, Haisco issued an announcement stating that its wholly-owned subsidiary, Liaoning Haisco Pharmaceuticals, had recently obtained the "Notice of Drug Clinical Trial Approval" issued by the Drug Evaluation Center of the State Drug Administration


    According to the "Drug Administration Law of the People's Republic of China" and related regulations, after review, the HSK21542 injection accepted on May 12, 2021 meets the relevant requirements of drug registration, and it is agreed to carry out the phase II clinical trial of "liver disease itching"


    HSK21542 has completed two phase I clinical trials in healthy people, and other INDs that have been applied for include two indications: acute and chronic pain (Phase Ⅲ in progress) and pruritus indication (Phase Ⅱ in progress)


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.